Denosumab Discontinuation-Denosumab Discontinuation

Video Transcription

Video Summary

The speaker begins by expressing gratitude for the opportunity to discuss the discontinuation of denosumab, a drug used to treat severe osteoporosis. They plan to present data on denosumab and its effectiveness, as well as discuss the findings and theories surrounding discontinuation of the treatment. They also mention a study they conducted on men with prostate cancer who discontinued denosumab. The speaker presents a figure comparing the efficacy of bisphosphonates and denosumab in preventing non-vertebral and hip fractures. They note that while both have similar effects in preventing fractures, denosumab demonstrates a continuing increase in bone mass and a reduction in fractures over a 10-year period. The speaker discusses a monkey study that suggests this continuing increase in bone mass may be due to modeling-based bone formation that continues despite denosumab treatment. The presenter also highlights the findings of the FREEDOM trial, which showed a reduction in fractures with denosumab treatment and the importance of increasing bone mineral density to prevent fractures. They discuss the discontinuation of denosumab, stating that bone loss and an increased risk of vertebral fractures are common risks. The speaker presents the results of a study on discontinuation in postmenopausal women, which showed a rapid loss of bone mineral density and increased bone turnover. They also mention other studies that support these findings. The presenter also touches on the use of bisphosphonates and solodronic acid as potential options for managing bone loss after discontinuation of denosumab. The speaker concludes by mentioning the need for an individualized approach to the treatment of osteoporosis and the importance of monitoring patients who discontinue denosumab. They also mention ongoing research and studies being conducted in this area.

Keywords

denosumab

osteoporosis

fracture prevention

bone mass

FREEDOM trial

bone mineral density

vertebral fractures

bisphosphonates


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274